Definitive Chemoradiation Therapy With Docetaxel, Cisplatin, and 5-Fluorouracil (DCF-R) in Advanced Esophageal Cancer: A Phase 2 Trial (KDOG 0501-P2)
A previous phase 1 study suggested that definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) is tolerable and active in patients with advanced esophageal cancer (AEC). This phase 2 study was designed to confirm the efficacy and toxicity of DCF-R in AEC. Patients wi...
Saved in:
| Published in | International journal of radiation oncology, biology, physics Vol. 89; no. 4; pp. 872 - 879 |
|---|---|
| Main Authors | , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Elsevier Inc
15.07.2014
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0360-3016 1879-355X 1879-355X |
| DOI | 10.1016/j.ijrobp.2014.03.030 |
Cover
| Abstract | A previous phase 1 study suggested that definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) is tolerable and active in patients with advanced esophageal cancer (AEC). This phase 2 study was designed to confirm the efficacy and toxicity of DCF-R in AEC.
Patients with previously untreated thoracic AEC who had T4 tumors or M1 lymph node metastasis (M1 LYM), or both, received intravenous infusions of docetaxel (35 mg/m2) and cisplatin (40 mg/m2) on day 1 and a continuous intravenous infusion of 5-fluorouracil (400 mg/m2/day) on days 1 to 5, every 2 weeks, plus concurrent radiation. The total radiation dose was initially 61.2 Gy but was lowered to multiple-field irradiation with 50.4 Gy to decrease esophagitis and late toxicity. Consequently, the number of cycles of DCF administered during radiation therapy was reduced from 4 to 3. The primary endpoint was the clinical complete response (cCR) rate.
Characteristics of the 42 subjects were: median age, 62 years; performance status, 0 in 14, 1 in 25, 2 in 3; TNM classification, T4M0 in 20, non-T4M1LYM in 12, T4M1LYM in 10; total scheduled radiation dose: 61.2 Gy in 12, 50.4 Gy in 30. The cCR rate was 52.4% (95% confidence interval [CI]: 37.3%-67.5%) overall, 33.3% in the 61.2-Gy group, and 60.0% in the 50.4-Gy group. The median progression-free survival was 11.1 months, and the median survival was 29.0 months with a survival rate of 43.9% at 3 years. Grade 3 or higher major toxicity consisted of leukopenia (71.4%), neutropenia (57.2%), anemia (16.7%), febrile neutropenia (38.1%), anorexia (31.0%), and esophagitis (28.6%).
DCF-R frequently caused myelosuppression and esophagitis but was highly active and suggested to be a promising regimen in AEC. On the basis of efficacy and safety, a radiation dose of 50.4 Gy is recommended for further studies of DCF-R. |
|---|---|
| AbstractList | A previous phase 1 study suggested that definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) is tolerable and active in patients with advanced esophageal cancer (AEC). This phase 2 study was designed to confirm the efficacy and toxicity of DCF-R in AEC.PURPOSEA previous phase 1 study suggested that definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) is tolerable and active in patients with advanced esophageal cancer (AEC). This phase 2 study was designed to confirm the efficacy and toxicity of DCF-R in AEC.Patients with previously untreated thoracic AEC who had T4 tumors or M1 lymph node metastasis (M1 LYM), or both, received intravenous infusions of docetaxel (35 mg/m(2)) and cisplatin (40 mg/m(2)) on day 1 and a continuous intravenous infusion of 5-fluorouracil (400 mg/m(2)/day) on days 1 to 5, every 2 weeks, plus concurrent radiation. The total radiation dose was initially 61.2 Gy but was lowered to multiple-field irradiation with 50.4 Gy to decrease esophagitis and late toxicity. Consequently, the number of cycles of DCF administered during radiation therapy was reduced from 4 to 3. The primary endpoint was the clinical complete response (cCR) rate.METHODS AND MATERIALSPatients with previously untreated thoracic AEC who had T4 tumors or M1 lymph node metastasis (M1 LYM), or both, received intravenous infusions of docetaxel (35 mg/m(2)) and cisplatin (40 mg/m(2)) on day 1 and a continuous intravenous infusion of 5-fluorouracil (400 mg/m(2)/day) on days 1 to 5, every 2 weeks, plus concurrent radiation. The total radiation dose was initially 61.2 Gy but was lowered to multiple-field irradiation with 50.4 Gy to decrease esophagitis and late toxicity. Consequently, the number of cycles of DCF administered during radiation therapy was reduced from 4 to 3. The primary endpoint was the clinical complete response (cCR) rate.Characteristics of the 42 subjects were: median age, 62 years; performance status, 0 in 14, 1 in 25, 2 in 3; TNM classification, T4M0 in 20, non-T4M1LYM in 12, T4M1LYM in 10; total scheduled radiation dose: 61.2 Gy in 12, 50.4 Gy in 30. The cCR rate was 52.4% (95% confidence interval [CI]: 37.3%-67.5%) overall, 33.3% in the 61.2-Gy group, and 60.0% in the 50.4-Gy group. The median progression-free survival was 11.1 months, and the median survival was 29.0 months with a survival rate of 43.9% at 3 years. Grade 3 or higher major toxicity consisted of leukopenia (71.4%), neutropenia (57.2%), anemia (16.7%), febrile neutropenia (38.1%), anorexia (31.0%), and esophagitis (28.6%).RESULTSCharacteristics of the 42 subjects were: median age, 62 years; performance status, 0 in 14, 1 in 25, 2 in 3; TNM classification, T4M0 in 20, non-T4M1LYM in 12, T4M1LYM in 10; total scheduled radiation dose: 61.2 Gy in 12, 50.4 Gy in 30. The cCR rate was 52.4% (95% confidence interval [CI]: 37.3%-67.5%) overall, 33.3% in the 61.2-Gy group, and 60.0% in the 50.4-Gy group. The median progression-free survival was 11.1 months, and the median survival was 29.0 months with a survival rate of 43.9% at 3 years. Grade 3 or higher major toxicity consisted of leukopenia (71.4%), neutropenia (57.2%), anemia (16.7%), febrile neutropenia (38.1%), anorexia (31.0%), and esophagitis (28.6%).DCF-R frequently caused myelosuppression and esophagitis but was highly active and suggested to be a promising regimen in AEC. On the basis of efficacy and safety, a radiation dose of 50.4 Gy is recommended for further studies of DCF-R.CONCLUSIONSDCF-R frequently caused myelosuppression and esophagitis but was highly active and suggested to be a promising regimen in AEC. On the basis of efficacy and safety, a radiation dose of 50.4 Gy is recommended for further studies of DCF-R. A previous phase 1 study suggested that definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) is tolerable and active in patients with advanced esophageal cancer (AEC). This phase 2 study was designed to confirm the efficacy and toxicity of DCF-R in AEC. Patients with previously untreated thoracic AEC who had T4 tumors or M1 lymph node metastasis (M1 LYM), or both, received intravenous infusions of docetaxel (35 mg/m(2)) and cisplatin (40 mg/m(2)) on day 1 and a continuous intravenous infusion of 5-fluorouracil (400 mg/m(2)/day) on days 1 to 5, every 2 weeks, plus concurrent radiation. The total radiation dose was initially 61.2 Gy but was lowered to multiple-field irradiation with 50.4 Gy to decrease esophagitis and late toxicity. Consequently, the number of cycles of DCF administered during radiation therapy was reduced from 4 to 3. The primary endpoint was the clinical complete response (cCR) rate. Characteristics of the 42 subjects were: median age, 62 years; performance status, 0 in 14, 1 in 25, 2 in 3; TNM classification, T4M0 in 20, non-T4M1LYM in 12, T4M1LYM in 10; total scheduled radiation dose: 61.2 Gy in 12, 50.4 Gy in 30. The cCR rate was 52.4% (95% confidence interval [CI]: 37.3%-67.5%) overall, 33.3% in the 61.2-Gy group, and 60.0% in the 50.4-Gy group. The median progression-free survival was 11.1 months, and the median survival was 29.0 months with a survival rate of 43.9% at 3 years. Grade 3 or higher major toxicity consisted of leukopenia (71.4%), neutropenia (57.2%), anemia (16.7%), febrile neutropenia (38.1%), anorexia (31.0%), and esophagitis (28.6%). DCF-R frequently caused myelosuppression and esophagitis but was highly active and suggested to be a promising regimen in AEC. On the basis of efficacy and safety, a radiation dose of 50.4 Gy is recommended for further studies of DCF-R. Purpose A previous phase 1 study suggested that definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) is tolerable and active in patients with advanced esophageal cancer (AEC). This phase 2 study was designed to confirm the efficacy and toxicity of DCF-R in AEC. Methods and Materials Patients with previously untreated thoracic AEC who had T4 tumors or M1 lymph node metastasis (M1 LYM), or both, received intravenous infusions of docetaxel (35 mg/m2 ) and cisplatin (40 mg/m2 ) on day 1 and a continuous intravenous infusion of 5-fluorouracil (400 mg/m2 /day) on days 1 to 5, every 2 weeks, plus concurrent radiation. The total radiation dose was initially 61.2 Gy but was lowered to multiple-field irradiation with 50.4 Gy to decrease esophagitis and late toxicity. Consequently, the number of cycles of DCF administered during radiation therapy was reduced from 4 to 3. The primary endpoint was the clinical complete response (cCR) rate. Results Characteristics of the 42 subjects were: median age, 62 years; performance status, 0 in 14, 1 in 25, 2 in 3; TNM classification, T4M0 in 20, non-T4M1LYM in 12, T4M1LYM in 10; total scheduled radiation dose: 61.2 Gy in 12, 50.4 Gy in 30. The cCR rate was 52.4% (95% confidence interval [CI]: 37.3%-67.5%) overall, 33.3% in the 61.2-Gy group, and 60.0% in the 50.4-Gy group. The median progression-free survival was 11.1 months, and the median survival was 29.0 months with a survival rate of 43.9% at 3 years. Grade 3 or higher major toxicity consisted of leukopenia (71.4%), neutropenia (57.2%), anemia (16.7%), febrile neutropenia (38.1%), anorexia (31.0%), and esophagitis (28.6%). Conclusions DCF-R frequently caused myelosuppression and esophagitis but was highly active and suggested to be a promising regimen in AEC. On the basis of efficacy and safety, a radiation dose of 50.4 Gy is recommended for further studies of DCF-R. A previous phase 1 study suggested that definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) is tolerable and active in patients with advanced esophageal cancer (AEC). This phase 2 study was designed to confirm the efficacy and toxicity of DCF-R in AEC. Patients with previously untreated thoracic AEC who had T4 tumors or M1 lymph node metastasis (M1 LYM), or both, received intravenous infusions of docetaxel (35 mg/m2) and cisplatin (40 mg/m2) on day 1 and a continuous intravenous infusion of 5-fluorouracil (400 mg/m2/day) on days 1 to 5, every 2 weeks, plus concurrent radiation. The total radiation dose was initially 61.2 Gy but was lowered to multiple-field irradiation with 50.4 Gy to decrease esophagitis and late toxicity. Consequently, the number of cycles of DCF administered during radiation therapy was reduced from 4 to 3. The primary endpoint was the clinical complete response (cCR) rate. Characteristics of the 42 subjects were: median age, 62 years; performance status, 0 in 14, 1 in 25, 2 in 3; TNM classification, T4M0 in 20, non-T4M1LYM in 12, T4M1LYM in 10; total scheduled radiation dose: 61.2 Gy in 12, 50.4 Gy in 30. The cCR rate was 52.4% (95% confidence interval [CI]: 37.3%-67.5%) overall, 33.3% in the 61.2-Gy group, and 60.0% in the 50.4-Gy group. The median progression-free survival was 11.1 months, and the median survival was 29.0 months with a survival rate of 43.9% at 3 years. Grade 3 or higher major toxicity consisted of leukopenia (71.4%), neutropenia (57.2%), anemia (16.7%), febrile neutropenia (38.1%), anorexia (31.0%), and esophagitis (28.6%). DCF-R frequently caused myelosuppression and esophagitis but was highly active and suggested to be a promising regimen in AEC. On the basis of efficacy and safety, a radiation dose of 50.4 Gy is recommended for further studies of DCF-R. Purpose: A previous phase 1 study suggested that definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) is tolerable and active in patients with advanced esophageal cancer (AEC). This phase 2 study was designed to confirm the efficacy and toxicity of DCF-R in AEC. Methods and Materials: Patients with previously untreated thoracic AEC who had T4 tumors or M1 lymph node metastasis (M1 LYM), or both, received intravenous infusions of docetaxel (35 mg/m{sup 2}) and cisplatin (40 mg/m{sup 2}) on day 1 and a continuous intravenous infusion of 5-fluorouracil (400 mg/m{sup 2}/day) on days 1 to 5, every 2 weeks, plus concurrent radiation. The total radiation dose was initially 61.2 Gy but was lowered to multiple-field irradiation with 50.4 Gy to decrease esophagitis and late toxicity. Consequently, the number of cycles of DCF administered during radiation therapy was reduced from 4 to 3. The primary endpoint was the clinical complete response (cCR) rate. Results: Characteristics of the 42 subjects were: median age, 62 years; performance status, 0 in 14, 1 in 25, 2 in 3; TNM classification, T4M0 in 20, non-T4M1LYM in 12, T4M1LYM in 10; total scheduled radiation dose: 61.2 Gy in 12, 50.4 Gy in 30. The cCR rate was 52.4% (95% confidence interval [CI]: 37.3%-67.5%) overall, 33.3% in the 61.2-Gy group, and 60.0% in the 50.4-Gy group. The median progression-free survival was 11.1 months, and the median survival was 29.0 months with a survival rate of 43.9% at 3 years. Grade 3 or higher major toxicity consisted of leukopenia (71.4%), neutropenia (57.2%), anemia (16.7%), febrile neutropenia (38.1%), anorexia (31.0%), and esophagitis (28.6%). Conclusions: DCF-R frequently caused myelosuppression and esophagitis but was highly active and suggested to be a promising regimen in AEC. On the basis of efficacy and safety, a radiation dose of 50.4 Gy is recommended for further studies of DCF-R. |
| Author | Katada, Natsuya Tanabe, Satoshi Koizumi, Wasaburo Sasaki, Tohru Ishido, Kenji Katada, Chikatoshi Komori, Shouko Higuchi, Katsuhiko Azuma, Mizutomo Ishiyama, Hiromichi Hayakawa, Kazushige |
| Author_xml | – sequence: 1 givenname: Katsuhiko surname: Higuchi fullname: Higuchi, Katsuhiko email: k.higu@kitasato-u.ac.jp organization: Department of Gastroenterology, Kitasato University East Hospital, Sagamihara, Kanagawa, Japan – sequence: 2 givenname: Shouko surname: Komori fullname: Komori, Shouko organization: Department of Radiology and Radiation Oncology, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan – sequence: 3 givenname: Satoshi surname: Tanabe fullname: Tanabe, Satoshi organization: Department of Gastroenterology, Kitasato University East Hospital, Sagamihara, Kanagawa, Japan – sequence: 4 givenname: Chikatoshi surname: Katada fullname: Katada, Chikatoshi organization: Department of Gastroenterology, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan – sequence: 5 givenname: Mizutomo surname: Azuma fullname: Azuma, Mizutomo organization: Department of Gastroenterology, Kitasato University East Hospital, Sagamihara, Kanagawa, Japan – sequence: 6 givenname: Hiromichi surname: Ishiyama fullname: Ishiyama, Hiromichi organization: Department of Radiology and Radiation Oncology, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan – sequence: 7 givenname: Tohru surname: Sasaki fullname: Sasaki, Tohru organization: Department of Gastroenterology, Kitasato University East Hospital, Sagamihara, Kanagawa, Japan – sequence: 8 givenname: Kenji surname: Ishido fullname: Ishido, Kenji organization: Department of Gastroenterology, Kitasato University East Hospital, Sagamihara, Kanagawa, Japan – sequence: 9 givenname: Natsuya surname: Katada fullname: Katada, Natsuya organization: Department of Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan – sequence: 10 givenname: Kazushige surname: Hayakawa fullname: Hayakawa, Kazushige organization: Department of Radiology and Radiation Oncology, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan – sequence: 11 givenname: Wasaburo surname: Koizumi fullname: Koizumi, Wasaburo organization: Department of Gastroenterology, Kitasato University East Hospital, Sagamihara, Kanagawa, Japan |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/24867539$$D View this record in MEDLINE/PubMed https://www.osti.gov/biblio/22420374$$D View this record in Osti.gov |
| BookMark | eNqVkl1rFDEUhgep2G31H4gEvNlCZ83XfBURltluFQstuqJ3IZs542SdTcZkdnF_iP_XTKd6IUgRAoHD877JOe85iY6MNRBFzwmeEUzSV5uZ3ji77mYUEz7DLBz8KJqQPCtiliRfjqIJZimOWYCPoxPvNxhjQjL-JDqmPE-zhBWT6OcCam10r_eAyga21slKy15bg1YNONkd0GfdN2hhFfTyB7TnqNS-awNizpE0FUriZbuzzu6cVLpF00W5jD-cIW3QvNpLo6BCl952jfwKskXlUHEXaI5uG-kBUbRyOtSn7xc3VwgnmMS39Oxp9LiWrYdn9_dp9Gl5uSrfxtc3V-_K-XWskjTv45riGivFeIVzqEgGCed5lapkXaRVxtacpLmiaSrruqgUB8YKXuQ1yQsFrJCUnUYvR1_rey280j2oRlljQPWCUk4xy3igpiPVOft9B74XW-0VtK00YHdekIQTltPsDn1xj-7WW6hE5_RWuoP4PfAA8BFQznrvoP6DECyGXMVGjLmKIVeBWTg4yC7-koW_3sXUO6nbh8RvRjGEUe41uKFTGJLRbmi0svp_DVQblkbJ9hscwG9C9ibEJIjwVGDxcdi7Ye0Ix5jlGQsGr_9t8PD7vwDyCOYH |
| CitedBy_id | crossref_primary_10_1080_15384047_2022_2156246 crossref_primary_10_1093_jjco_hyw195 crossref_primary_10_5301_tj_5000234 crossref_primary_10_1186_s13014_021_01821_6 crossref_primary_10_3390_cancers15010010 crossref_primary_10_1080_0284186X_2017_1307518 crossref_primary_10_1016_j_canrad_2018_10_005 crossref_primary_10_1007_s10147_018_1240_4 crossref_primary_10_5833_jjgs_2016_0183 crossref_primary_10_1007_s00268_018_4536_7 crossref_primary_10_1586_14737140_2015_1074041 crossref_primary_10_1093_jrr_rraa008 crossref_primary_10_1007_s10388_019_00709_5 crossref_primary_10_1002_cam4_3724 crossref_primary_10_12998_wjcc_v8_i10_1950 crossref_primary_10_4103_JCRP_JCRP_19_20 crossref_primary_10_1002_pro6_1201 crossref_primary_10_1007_s10388_018_0627_7 crossref_primary_10_14309_crj_0000000000001097 crossref_primary_10_1007_s00595_015_1116_4 crossref_primary_10_1111_dote_12506 crossref_primary_10_1007_s11604_017_0693_0 crossref_primary_10_1007_s10147_015_0896_2 crossref_primary_10_1002_cncr_30823 crossref_primary_10_1016_j_adro_2016_07_002 crossref_primary_10_7759_cureus_18894 crossref_primary_10_1080_17512433_2017_1313112 crossref_primary_10_1007_s00595_024_02867_1 crossref_primary_10_1016_j_canrad_2022_06_021 crossref_primary_10_3390_cancers16030658 crossref_primary_10_1111_dote_12471 crossref_primary_10_14789_jmj_2018_64_JMJ17_OA03 crossref_primary_10_1186_s13014_020_01518_2 crossref_primary_10_1111_dote_12433 crossref_primary_10_1002_ijc_34030 crossref_primary_10_1007_s11748_016_0626_3 crossref_primary_10_1097_MD_0000000000018732 crossref_primary_10_35772_ghm_2020_01090 crossref_primary_10_1016_j_bpg_2018_11_011 crossref_primary_10_1016_j_ijrobp_2015_05_041 crossref_primary_10_4103_jcrt_jcrt_1627_22 crossref_primary_10_1111_ajco_12995 crossref_primary_10_18632_oncotarget_15665 crossref_primary_10_1097_MD_0000000000007920 crossref_primary_10_1245_s10434_015_4556_6 crossref_primary_10_1016_j_radonc_2023_109700 crossref_primary_10_1007_s00280_016_3062_2 crossref_primary_10_1007_s00280_018_03764_4 crossref_primary_10_1007_s10388_018_0641_9 crossref_primary_10_1093_jjco_hyw082 crossref_primary_10_1007_s00595_019_01878_7 crossref_primary_10_3892_or_2024_8724 crossref_primary_10_1002_ags3_12222 crossref_primary_10_1007_s00280_019_03835_0 crossref_primary_10_1007_s10388_023_00993_2 |
| Cites_doi | 10.1016/j.radonc.2010.10.021 10.1056/NEJM199608153350702 10.1016/j.ijrobp.2010.06.033 10.1093/jjco/hyh107 10.1053/j.seminoncol.2005.04.005 10.1002/cncr.27822 10.1016/j.radonc.2008.03.006 10.1200/JCO.1999.17.9.2915 10.1007/BF02993858 10.1001/jama.281.17.1623 10.1056/NEJM199812313392704 10.3727/0965040041791455 10.1200/JCO.20.5.1167 10.1200/JCO.2005.00.034 10.1200/JCO.1997.15.1.277 10.1200/JCO.1998.16.5.1826 10.1093/jnci/92.3.205 10.1016/S1470-2045(13)70136-0 10.1007/s10388-008-0151-2 10.1093/annonc/mdh231 10.1056/NEJM199504133321507 10.1200/JCO.2009.24.8773 10.1245/s10434-012-2822-4 10.1016/j.radonc.2008.09.025 10.1200/JCO.2005.04.7118 10.1200/JCO.2003.03.055 |
| ContentType | Journal Article |
| Copyright | 2014 Elsevier Inc. Elsevier Inc. Copyright © 2014 Elsevier Inc. All rights reserved. |
| Copyright_xml | – notice: 2014 Elsevier Inc. – notice: Elsevier Inc. – notice: Copyright © 2014 Elsevier Inc. All rights reserved. |
| CorporateAuthor | Kitasato Digestive Disease and Oncology Group |
| CorporateAuthor_xml | – name: Kitasato Digestive Disease and Oncology Group |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 OTOTI |
| DOI | 10.1016/j.ijrobp.2014.03.030 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic OSTI.GOV |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1879-355X |
| EndPage | 879 |
| ExternalDocumentID | 22420374 24867539 10_1016_j_ijrobp_2014_03_030 S0360301614003873 1_s2_0_S0360301614003873 |
| Genre | Clinical Trial, Phase II Journal Article |
| GroupedDBID | --- --K .1- .FO 0R~ 1B1 1P~ 1RT 1~5 4.4 457 4G. 53G 5RE 5VS 7-5 AAEDT AAEDW AAQFI AAQQT AAWTL AAXUO ABJNI ABLJU ABNEU ABOCM ABUDA ACGFS ACIUM ACVFH ADBBV ADCNI ADVLN AENEX AEUPX AEVXI AFPUW AFRHN AFTJW AGCQF AHHHB AIGII AITUG AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ BELOY DU5 EBS EFKBS EJD F5P FDB GBLVA HED HMO IHE J1W KOM LX3 M41 MO0 O9- OC~ OO- RNS ROL RPZ SDG SEL SES SSZ UV1 XH2 Z5R ~S- .55 .GJ 29J AALRI AAQXK ABEFU ABWVN ACRPL ADMUD ADNMO ADPAM AFCTW AFFNX AFJKZ AGRDE ASPBG AVWKF AZFZN EFJIC FEDTE FGOYB FIRID G-2 HMK HVGLF HX~ HZ~ NQ- R2- RIG SAE SEW UDS X7M XPP ZGI AAIAV AGZHU ALXNB ZA5 AAYWO AAYXX AGQPQ CITATION CGR CUY CVF ECM EIF NPM 7X8 ABPTK OTOTI |
| ID | FETCH-LOGICAL-c568t-f20f0cc34d08ed17e5448d6c5b96d73b4168c266aff9dc4e339498f189ce39a23 |
| ISSN | 0360-3016 1879-355X |
| IngestDate | Thu May 18 18:35:40 EDT 2023 Fri Sep 05 08:13:35 EDT 2025 Thu Apr 03 07:02:29 EDT 2025 Tue Jul 01 01:49:11 EDT 2025 Thu Apr 24 23:10:37 EDT 2025 Fri Feb 23 02:33:32 EST 2024 Sun Feb 23 10:18:55 EST 2025 Tue Aug 26 16:37:46 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Language | English |
| License | Copyright © 2014 Elsevier Inc. All rights reserved. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c568t-f20f0cc34d08ed17e5448d6c5b96d73b4168c266aff9dc4e339498f189ce39a23 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
| PMID | 24867539 |
| PQID | 1541382774 |
| PQPubID | 23479 |
| PageCount | 8 |
| ParticipantIDs | osti_scitechconnect_22420374 proquest_miscellaneous_1541382774 pubmed_primary_24867539 crossref_primary_10_1016_j_ijrobp_2014_03_030 crossref_citationtrail_10_1016_j_ijrobp_2014_03_030 elsevier_sciencedirect_doi_10_1016_j_ijrobp_2014_03_030 elsevier_clinicalkeyesjournals_1_s2_0_S0360301614003873 elsevier_clinicalkey_doi_10_1016_j_ijrobp_2014_03_030 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2014-07-15 |
| PublicationDateYYYYMMDD | 2014-07-15 |
| PublicationDate_xml | – month: 07 year: 2014 text: 2014-07-15 day: 15 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | International journal of radiation oncology, biology, physics |
| PublicationTitleAlternate | Int J Radiat Oncol Biol Phys |
| PublicationYear | 2014 |
| Publisher | Elsevier Inc |
| Publisher_xml | – name: Elsevier Inc |
| References | Cooper, Guo, Herskovic (bib3) 1999; 281 Shinoda, Ando, Kato (bib20) 2010; 28 Onozawa, Nihei, Ishikura (bib25) 2009; 92 Muro, Hamaguchi, Ohtsu (bib11) 2004; 15 Einzig, Neuberg, Remick (bib10) 1996; 13 Bedenne, Michel, Bouche (bib5) 2007; 25 Rowinsky, Donehower (bib14) 1995; 332 Al-Sarraf, Martz, Herskovic (bib27) 1997; 15 Higuchi, Koizumi, Tanabe (bib15) 2008; 87 Dunne, Mothersill, Robson (bib13) 2004; 14 Kato, Muro, Minashi (bib19) 2011; 81 Yamashita, Okuma, Wakui (bib26) 2011; 98 Therasse, Arbuck, Eisenhauer (bib16) 2000; 92 Minsky, Pajak, Ginsberg (bib4) 2002; 20 Walsh, Noonan, Hollywood (bib1) 1996; 335 Zanoni, Verlato, Giacopuzzi (bib22) 2013; 20 Rigas, Dragnev, Bubis (bib9) 2005; 32 Crosby, Hurt, Falk (bib24) 2013; 14 Spigel, Greco, Meluch (bib23) 2010; 28 Kuwano, Nishimura, Ohtsu (bib17) 2008; 5 Kelsen, Ginsberg, Pajak (bib2) 1998; 339 Stahl, Stuschke, Lehmann (bib6) 2005; 23 Ohtsu, Boku, Muro (bib7) 1999; 17 Pasini, de Manzoni, Zanoni (bib21) 2013; 119 Ishikura, Nihei, Ohtsu (bib18) 2003; 21 Ishida, Ando, Yamamoto (bib8) 2004; 34 Shah, Shibata, Stoller (bib28) 2010; 28 Ilson, Ajani, Bhalla (bib12) 1998; 16 Rigas (10.1016/j.ijrobp.2014.03.030_bib9) 2005; 32 Higuchi (10.1016/j.ijrobp.2014.03.030_bib15) 2008; 87 Shinoda (10.1016/j.ijrobp.2014.03.030_bib20) 2010; 28 Walsh (10.1016/j.ijrobp.2014.03.030_bib1) 1996; 335 Kato (10.1016/j.ijrobp.2014.03.030_bib19) 2011; 81 Minsky (10.1016/j.ijrobp.2014.03.030_bib4) 2002; 20 Onozawa (10.1016/j.ijrobp.2014.03.030_bib25) 2009; 92 Zanoni (10.1016/j.ijrobp.2014.03.030_bib22) 2013; 20 Einzig (10.1016/j.ijrobp.2014.03.030_bib10) 1996; 13 Cooper (10.1016/j.ijrobp.2014.03.030_bib3) 1999; 281 Ohtsu (10.1016/j.ijrobp.2014.03.030_bib7) 1999; 17 Bedenne (10.1016/j.ijrobp.2014.03.030_bib5) 2007; 25 Dunne (10.1016/j.ijrobp.2014.03.030_bib13) 2004; 14 Yamashita (10.1016/j.ijrobp.2014.03.030_bib26) 2011; 98 Crosby (10.1016/j.ijrobp.2014.03.030_bib24) 2013; 14 Al-Sarraf (10.1016/j.ijrobp.2014.03.030_bib27) 1997; 15 Muro (10.1016/j.ijrobp.2014.03.030_bib11) 2004; 15 Pasini (10.1016/j.ijrobp.2014.03.030_bib21) 2013; 119 Rowinsky (10.1016/j.ijrobp.2014.03.030_bib14) 1995; 332 Kuwano (10.1016/j.ijrobp.2014.03.030_bib17) 2008; 5 Spigel (10.1016/j.ijrobp.2014.03.030_bib23) 2010; 28 Ishikura (10.1016/j.ijrobp.2014.03.030_bib18) 2003; 21 Ilson (10.1016/j.ijrobp.2014.03.030_bib12) 1998; 16 Shah (10.1016/j.ijrobp.2014.03.030_bib28) 2010; 28 Ishida (10.1016/j.ijrobp.2014.03.030_bib8) 2004; 34 Kelsen (10.1016/j.ijrobp.2014.03.030_bib2) 1998; 339 Therasse (10.1016/j.ijrobp.2014.03.030_bib16) 2000; 92 Stahl (10.1016/j.ijrobp.2014.03.030_bib6) 2005; 23 |
| References_xml | – volume: 98 start-page: 255 year: 2011 end-page: 260 ident: bib26 article-title: Details of recurrence sites after elective nodal irradiation (ENI) using 3D-conformal radiotherapy (3D-CRT) combined with chemotherapy for thoracic esophageal squamous cell carcinoma–a retrospective analysis publication-title: Radiother Oncol – volume: 14 start-page: 447 year: 2004 end-page: 454 ident: bib13 article-title: Radiosensitization of colon cancer cell lines by docetaxel: Mechanisms of action publication-title: Oncol Res – volume: 34 start-page: 615 year: 2004 end-page: 619 ident: bib8 article-title: Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: A Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516) publication-title: Jpn J Clin Oncol – volume: 16 start-page: 1826 year: 1998 end-page: 1834 ident: bib12 article-title: Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus publication-title: J Clin Oncol – volume: 25 start-page: 1160 year: 2007 end-page: 1168 ident: bib5 article-title: Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102 publication-title: J Clin Oncol – volume: 14 start-page: 627 year: 2013 end-page: 637 ident: bib24 article-title: Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): A multicentre, phase 2/3 randomised trial publication-title: Lancet Oncol – volume: 28 start-page: 2213 year: 2010 end-page: 2219 ident: bib23 article-title: Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction publication-title: J Clin Oncol – volume: 92 start-page: 205 year: 2000 end-page: 216 ident: bib16 article-title: New guidelines to evaluate the response to treatment in solid tumors publication-title: J Natl Cancer Inst – volume: 5 start-page: 61 year: 2008 end-page: 73 ident: bib17 article-title: Guidelines for diagnosis and treatment of carcinoma of the esophagus April 2007 edition publication-title: Esophagus – volume: 15 start-page: 955 year: 2004 end-page: 959 ident: bib11 article-title: A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer publication-title: Ann Oncol – volume: 17 start-page: 2915 year: 1999 end-page: 2921 ident: bib7 article-title: Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus publication-title: J Clin Oncol – volume: 28 start-page: 15s year: 2010 ident: bib20 article-title: A multicenter randomized phase II (rPII)/III study comparing concurrent chemoradiotherapy (CRT) with low-dose cisplatin plus continuous infusion of 5-fluorouracil (LDPF) and standard-dose PF (SDPF) for locally advanced unresectable squamous cell carcinoma of the thoracic esophagus (JCOG0303) publication-title: J Clin Oncol – volume: 87 start-page: 398 year: 2008 end-page: 404 ident: bib15 article-title: A phase I trial of definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced esophageal carcinoma: Kitasato digestive disease & oncology group trial (KDOG 0501) publication-title: Radiother Oncol – volume: 81 start-page: 684 year: 2011 end-page: 690 ident: bib19 article-title: Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906) publication-title: Int J Radiat Oncol Biol Phys – volume: 15 start-page: 277 year: 1997 end-page: 284 ident: bib27 article-title: Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study publication-title: J Clin Oncol – volume: 28 start-page: 15s year: 2010 ident: bib28 article-title: Random assignment multicenter phase II study of modified docetaxel, cisplatin, fluorouracil (mDCF) versus DCF with growth factor support (GCSF) in metastatic gastroesophageal adenocarcinoma (GE) publication-title: J Clin Oncol – volume: 23 start-page: 2310 year: 2005 end-page: 2317 ident: bib6 article-title: Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus publication-title: J Clin Oncol – volume: 20 start-page: 1993 year: 2013 end-page: 1999 ident: bib22 article-title: Neoadjuvant concurrent chemoradiotherapy for locally advanced esophageal cancer in a single high-volume center publication-title: Ann Surg Oncol – volume: 92 start-page: 266 year: 2009 end-page: 269 ident: bib25 article-title: Elective nodal irradiation (ENI) in definitive chemoradiotherapy (CRT) for squamous cell carcinoma of the thoracic esophagus publication-title: Radiother Oncol – volume: 332 start-page: 1004 year: 1995 end-page: 1014 ident: bib14 article-title: Paclitaxel (taxol) publication-title: N Engl J Med – volume: 281 start-page: 1623 year: 1999 end-page: 1627 ident: bib3 article-title: Chemoradiotherapy of locally advanced esophageal cancer: Long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group publication-title: JAMA – volume: 13 start-page: 87 year: 1996 end-page: 93 ident: bib10 article-title: Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: The Eastern Cooperative Oncology Group (ECOG) results of protocol E1293 publication-title: Med Oncol – volume: 32 start-page: S39 year: 2005 end-page: S51 ident: bib9 article-title: Docetaxel in the treatment of esophageal cancer publication-title: Semin Oncol – volume: 119 start-page: 939 year: 2013 end-page: 945 ident: bib21 article-title: Neoadjuvant therapy with weekly docetaxel and cisplatin, 5-fluorouracil continuous infusion, and concurrent radiotherapy in patients with locally advanced esophageal cancer produced a high percentage of long-lasting pathological complete response: A phase 2 study publication-title: Cancer – volume: 339 start-page: 1979 year: 1998 end-page: 1984 ident: bib2 article-title: Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer publication-title: N Engl J Med – volume: 21 start-page: 2697 year: 2003 end-page: 2702 ident: bib18 article-title: Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus publication-title: J Clin Oncol – volume: 335 start-page: 462 year: 1996 end-page: 467 ident: bib1 article-title: A comparison of multimodal therapy and surgery for esophageal adenocarcinoma publication-title: N Engl J Med – volume: 20 start-page: 1167 year: 2002 end-page: 1174 ident: bib4 article-title: INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: High-dose versus standard-dose radiation therapy publication-title: J Clin Oncol – volume: 98 start-page: 255 year: 2011 ident: 10.1016/j.ijrobp.2014.03.030_bib26 article-title: Details of recurrence sites after elective nodal irradiation (ENI) using 3D-conformal radiotherapy (3D-CRT) combined with chemotherapy for thoracic esophageal squamous cell carcinoma–a retrospective analysis publication-title: Radiother Oncol doi: 10.1016/j.radonc.2010.10.021 – volume: 335 start-page: 462 year: 1996 ident: 10.1016/j.ijrobp.2014.03.030_bib1 article-title: A comparison of multimodal therapy and surgery for esophageal adenocarcinoma publication-title: N Engl J Med doi: 10.1056/NEJM199608153350702 – volume: 81 start-page: 684 year: 2011 ident: 10.1016/j.ijrobp.2014.03.030_bib19 article-title: Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906) publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2010.06.033 – volume: 34 start-page: 615 year: 2004 ident: 10.1016/j.ijrobp.2014.03.030_bib8 article-title: Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: A Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516) publication-title: Jpn J Clin Oncol doi: 10.1093/jjco/hyh107 – volume: 32 start-page: S39 year: 2005 ident: 10.1016/j.ijrobp.2014.03.030_bib9 article-title: Docetaxel in the treatment of esophageal cancer publication-title: Semin Oncol doi: 10.1053/j.seminoncol.2005.04.005 – volume: 119 start-page: 939 year: 2013 ident: 10.1016/j.ijrobp.2014.03.030_bib21 publication-title: Cancer doi: 10.1002/cncr.27822 – volume: 87 start-page: 398 year: 2008 ident: 10.1016/j.ijrobp.2014.03.030_bib15 article-title: A phase I trial of definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced esophageal carcinoma: Kitasato digestive disease & oncology group trial (KDOG 0501) publication-title: Radiother Oncol doi: 10.1016/j.radonc.2008.03.006 – volume: 17 start-page: 2915 year: 1999 ident: 10.1016/j.ijrobp.2014.03.030_bib7 article-title: Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus publication-title: J Clin Oncol doi: 10.1200/JCO.1999.17.9.2915 – volume: 13 start-page: 87 year: 1996 ident: 10.1016/j.ijrobp.2014.03.030_bib10 article-title: Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: The Eastern Cooperative Oncology Group (ECOG) results of protocol E1293 publication-title: Med Oncol doi: 10.1007/BF02993858 – volume: 281 start-page: 1623 year: 1999 ident: 10.1016/j.ijrobp.2014.03.030_bib3 article-title: Chemoradiotherapy of locally advanced esophageal cancer: Long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group publication-title: JAMA doi: 10.1001/jama.281.17.1623 – volume: 339 start-page: 1979 year: 1998 ident: 10.1016/j.ijrobp.2014.03.030_bib2 article-title: Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer publication-title: N Engl J Med doi: 10.1056/NEJM199812313392704 – volume: 14 start-page: 447 year: 2004 ident: 10.1016/j.ijrobp.2014.03.030_bib13 article-title: Radiosensitization of colon cancer cell lines by docetaxel: Mechanisms of action publication-title: Oncol Res doi: 10.3727/0965040041791455 – volume: 20 start-page: 1167 year: 2002 ident: 10.1016/j.ijrobp.2014.03.030_bib4 article-title: INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: High-dose versus standard-dose radiation therapy publication-title: J Clin Oncol doi: 10.1200/JCO.20.5.1167 – volume: 23 start-page: 2310 year: 2005 ident: 10.1016/j.ijrobp.2014.03.030_bib6 article-title: Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus publication-title: J Clin Oncol doi: 10.1200/JCO.2005.00.034 – volume: 15 start-page: 277 year: 1997 ident: 10.1016/j.ijrobp.2014.03.030_bib27 article-title: Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study publication-title: J Clin Oncol doi: 10.1200/JCO.1997.15.1.277 – volume: 28 start-page: 15s issue: suppl year: 2010 ident: 10.1016/j.ijrobp.2014.03.030_bib28 article-title: Random assignment multicenter phase II study of modified docetaxel, cisplatin, fluorouracil (mDCF) versus DCF with growth factor support (GCSF) in metastatic gastroesophageal adenocarcinoma (GE) publication-title: J Clin Oncol – volume: 16 start-page: 1826 year: 1998 ident: 10.1016/j.ijrobp.2014.03.030_bib12 article-title: Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus publication-title: J Clin Oncol doi: 10.1200/JCO.1998.16.5.1826 – volume: 92 start-page: 205 year: 2000 ident: 10.1016/j.ijrobp.2014.03.030_bib16 article-title: New guidelines to evaluate the response to treatment in solid tumors publication-title: J Natl Cancer Inst doi: 10.1093/jnci/92.3.205 – volume: 14 start-page: 627 year: 2013 ident: 10.1016/j.ijrobp.2014.03.030_bib24 article-title: Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): A multicentre, phase 2/3 randomised trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(13)70136-0 – volume: 5 start-page: 61 year: 2008 ident: 10.1016/j.ijrobp.2014.03.030_bib17 article-title: Guidelines for diagnosis and treatment of carcinoma of the esophagus April 2007 edition publication-title: Esophagus doi: 10.1007/s10388-008-0151-2 – volume: 15 start-page: 955 year: 2004 ident: 10.1016/j.ijrobp.2014.03.030_bib11 article-title: A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer publication-title: Ann Oncol doi: 10.1093/annonc/mdh231 – volume: 332 start-page: 1004 year: 1995 ident: 10.1016/j.ijrobp.2014.03.030_bib14 article-title: Paclitaxel (taxol) publication-title: N Engl J Med doi: 10.1056/NEJM199504133321507 – volume: 28 start-page: 15s issue: suppl year: 2010 ident: 10.1016/j.ijrobp.2014.03.030_bib20 publication-title: J Clin Oncol – volume: 28 start-page: 2213 year: 2010 ident: 10.1016/j.ijrobp.2014.03.030_bib23 article-title: Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction publication-title: J Clin Oncol doi: 10.1200/JCO.2009.24.8773 – volume: 20 start-page: 1993 year: 2013 ident: 10.1016/j.ijrobp.2014.03.030_bib22 article-title: Neoadjuvant concurrent chemoradiotherapy for locally advanced esophageal cancer in a single high-volume center publication-title: Ann Surg Oncol doi: 10.1245/s10434-012-2822-4 – volume: 92 start-page: 266 year: 2009 ident: 10.1016/j.ijrobp.2014.03.030_bib25 article-title: Elective nodal irradiation (ENI) in definitive chemoradiotherapy (CRT) for squamous cell carcinoma of the thoracic esophagus publication-title: Radiother Oncol doi: 10.1016/j.radonc.2008.09.025 – volume: 25 start-page: 1160 year: 2007 ident: 10.1016/j.ijrobp.2014.03.030_bib5 article-title: Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102 publication-title: J Clin Oncol doi: 10.1200/JCO.2005.04.7118 – volume: 21 start-page: 2697 year: 2003 ident: 10.1016/j.ijrobp.2014.03.030_bib18 article-title: Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus publication-title: J Clin Oncol doi: 10.1200/JCO.2003.03.055 |
| SSID | ssj0001174 |
| Score | 2.3995094 |
| Snippet | A previous phase 1 study suggested that definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) is tolerable and active in... Purpose A previous phase 1 study suggested that definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) is tolerable and active... Purpose: A previous phase 1 study suggested that definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) is tolerable and... |
| SourceID | osti proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 872 |
| SubjectTerms | Aged Anemia - etiology ANOREXIA Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carcinoma, Squamous Cell - mortality Carcinoma, Squamous Cell - pathology Carcinoma, Squamous Cell - therapy Chemoradiotherapy - adverse effects Chemoradiotherapy - methods CHEMOTHERAPY Cisplatin - administration & dosage CLASSIFICATION Disease-Free Survival Drug Administration Schedule Esophageal Neoplasms - mortality Esophageal Neoplasms - pathology Esophageal Neoplasms - therapy Esophagitis - prevention & control ESOPHAGUS Feasibility Studies Febrile Neutropenia Female Fluorouracil - administration & dosage Hematology, Oncology and Palliative Medicine Humans IRRADIATION LEUKOPENIA Leukopenia - etiology LYMPH NODES Lymphatic Irradiation - methods Lymphatic Metastasis Male METASTASES Middle Aged Neoplasm Staging NEOPLASMS Neutropenia - etiology PATIENTS RADIATION DOSES Radiology RADIOLOGY AND NUCLEAR MEDICINE RADIOTHERAPY Radiotherapy Dosage Taxoids - administration & dosage TOXICITY URACILS |
| Title | Definitive Chemoradiation Therapy With Docetaxel, Cisplatin, and 5-Fluorouracil (DCF-R) in Advanced Esophageal Cancer: A Phase 2 Trial (KDOG 0501-P2) |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0360301614003873 https://www.clinicalkey.es/playcontent/1-s2.0-S0360301614003873 https://dx.doi.org/10.1016/j.ijrobp.2014.03.030 https://www.ncbi.nlm.nih.gov/pubmed/24867539 https://www.proquest.com/docview/1541382774 https://www.osti.gov/biblio/22420374 |
| Volume | 89 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ta9swEBZtCmNfxt7XrRsa7ENL62LLcmzvW0jalYVupS-s34wsy4uzYpfYgbH_sf-7O0u2E5rSrhBMMCdb9umR7s7PnQj5ZIs4BocNBm_fTy2uXGYJWFmsWLIE4GT3w7o6__G3_tEF_3rpXa6thwuspXkV78s_K_NKHqJVOAd6xSzZ_9Bse1E4Af9Bv3AEDcPxXjoeqTQz5B9M_AdtJvpNI5ECiwUA6KsJGMlSVeK3_h4_zMpr5L_lDW_Tsw6v5sUM7idkdoUW52h4aJ1iuABjIQ1H4AD3O4DJB4MNeGamc9pPJrAM7rLd83r3D2g8Hn3_smt7tmOdsCbMMO3o8l30caFmRdfvIpdt-kzcZdLo-Etr_h9lP3EPF8MGKeeT7Fcd8T0e6RhRy2IeF_BSarmzSTFvhLpoRS5iHYIXVVHqC968hqhEIjQ1oU63WiloAicOx4isTh1tE8ZgCbJ1qmezGOj9jMyg5wsze6B3GGqNhHDl-qNDIdP9bDorYiyH6vC6hq759rRU7vtgOHasku3b1hl2BXsC3i7SCdxlYe2sRSWL7OiG6DrZYL6PDIWNwfj0x7g1QxxTgrx5yiZvtCY33uzfbXZZr4Cl5nb3qzbDzp-SJ8Z_ogMNhmdkTeXPyaNjwxB5Qf52mKDLmKAGExQxQVtM7NEWEXsU8ECX8UC3azTs0CynDRZohwWqsfCZDmiNBMpojQS6jTigBgc7L8nF4cH58MgyW49Y0usHlZUyO7WldHliBypxfOVxHiR96cVhP_HdGNyYQIJtK9I0TCRMcW7IwyB1glAqNxTMfUV6eZGrN4T6QaoYT3xPSJRJQizByX1PuYLH0mObxG1efCRNXX7cHuYqagiY00irK0J1RbYLP3uTWG2ra12X5g55r9Fp1ORcg5UQwcC9o52_qp0qzSRRRrcNzMWWxprXVvo97rmFgw5bYSFriYw_aAbOBsNqWZvkYzMYI1gL8QOnyFUxh654HEuq-ijzWo_S9uUwLC3queHbBz_QO_K4m0a2SK-azdV78Eiq-IPB3j8PdimI |
| linkProvider | Library Specific Holdings |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Definitive+Chemoradiation+Therapy+With+Docetaxel%2C+Cisplatin%2C+and+5-Fluorouracil+%28DCF-R%29+in+Advanced+Esophageal+Cancer%3A+A+Phase+2+Trial+%28KDOG+0501-P2%29&rft.jtitle=International+journal+of+radiation+oncology%2C+biology%2C+physics&rft.au=Higuchi%2C+Katsuhiko%2C+MD%2C+PhD&rft.au=Komori%2C+Shouko%2C+MD&rft.au=Tanabe%2C+Satoshi%2C+MD%2C+PhD&rft.au=Katada%2C+Chikatoshi%2C+MD%2C+PhD&rft.date=2014-07-15&rft.issn=0360-3016&rft.volume=89&rft.issue=4&rft.spage=872&rft.epage=879&rft_id=info:doi/10.1016%2Fj.ijrobp.2014.03.030&rft.externalDBID=ECK1-s2.0-S0360301614003873&rft.externalDocID=1_s2_0_S0360301614003873 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F03603016%2FS0360301614X00088%2Fcov150h.gif |